Zenas BioPharma, Inc. (ZBIO)
Develops antibody drugs to treat autoimmune and inflammatory diseases like lupus and multiple sclerosis.
$32.29-0.02%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+109.5%
The outlook
ZBIO trades at $32.29, positioned solidly above both its 50- and 200-day moving averages with strong upward momentum in its recent trend. Analyst consensus is strongly bullish, with an average price target sitting roughly 35% above the current price. The stock sits about midway through its 52-week range, having recovered significantly from its lows.
What’s behind the score
Analyst consensusStrong Buy — 1.3 avg of 8 analysts
Price trendAbove its 50- & 200-day averages
52-week range60% of the way from its 52-week low to high
Price targetAvg target +35% vs current price
Analyst price target
~12-month · 8 analysts$43.50average target+34.7% vs now
Now $32.29
Low $22.00High $59.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
—
52-wk high
$44.60
52-wk low
$13.50
50-day avg
$23.05
200-day avg
$25.63
Trailing P/E
—